CMPX Compass Therapeutics, Inc.
8-K Current Report
Filed: March 5, 2026
Health Care
Biological Products, (No Diagnostic Substances)Compass Therapeutics, Inc. (CMPX) 8-K current report filed with SEC EDGAR on March 5, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 2.02: Results of Operations and Financial Condition
AI Filing Analysis8-K
Item 2.02 · Results of Operations and Financial Condition
- • Q4/full-year 2025 earnings disclosure filed March 5, 2026 — full results in referenced exhibit, not detailed in this item text
- • Neil Lerner, Chief Accounting Officer, signed filing — no CFO signature, notable for a small-cap biotech
Get deeper insights on Compass Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.